Literature DB >> 19370627

Interventions for improving adherence to ocular hypotensive therapy.

Trish A Gray1, Lois C Orton, David Henson, Robert Harper, Heather Waterman.   

Abstract

BACKGROUND: Poor adherence to therapy is a significant healthcare issue, particularly in patients with chronic disease such as open angle glaucoma. Treatment failure may necessitate unwarranted changes of medications, increased healthcare expenditure and risk to the patient if surgical intervention is required. Simplifying eye drop regimes, providing adequate information and ongoing support according to patient need, may have a positive effect on improving adherence.
OBJECTIVES: To summarise the effects of interventions for improving adherence to ocular hypotensive therapy in people with ocular hypertension (OHT) or glaucoma. SEARCH STRATEGY: We searched CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, Web of Science, ZETOC and OpenSIGLE. In addition, we searched research registers of ongoing studies. We contacted pharmaceutical manufacturers to request unpublished data and searched conference proceedings for the Association for Research in Vision and Ophthalmology (ARVO), and the Annual Congress for the Royal College of Ophthalmologists (RCO). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 15 January 2009. SELECTION CRITERIA: We included randomised controlled trials (RCTs) and quasi RCTs that compared interventions to improve adherence to ocular hypotensive therapy for patients with OHT or glaucoma. DATA COLLECTION AND ANALYSIS: At least two authors independently assessed the search results for eligibility and extracted data for included trials onto specifically designed forms. We calculated the mean difference for continuous data and relative risks for dichotomous data. Where appropriate, we pooled data using a fixed-effect model. MAIN
RESULTS: Eight trials met the inclusion criteria. There was considerable heterogeneity of interventions and reported outcome measures and therefore, meta-analysis was limited to two studies. Overall, studies were not of high quality due to small sample sizes, missing data and short term follow-up. Three of five drug comparison studies provided evidence that reducing the frequency of drops can improve adherence. However, the study that compared the least frequent regime with one of the most complicated, showed no difference in reported adherence. A small study of thirteen patients found a reminder device beneficial to adherence levels yet only one of two studies involving education and individualised care planning was found to be successful. AUTHORS'
CONCLUSIONS: Interventions involving simplified dosing regimes, reminder devices, education and individualised care planning, did show improvements in adherence rates. However, due to inadequate methodological quality and heterogeneity of study design we are unable to advocate any particular interventions at this time.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19370627     DOI: 10.1002/14651858.CD006132.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  16 in total

1.  What comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities.

Authors:  Tianjing Li; S Swaroop Vedula; Roberta Scherer; Kay Dickersin
Journal:  Ann Intern Med       Date:  2012-03-06       Impact factor: 25.391

2.  Impact of a health communication intervention to improve glaucoma treatment adherence. Results of the interactive study to increase glaucoma adherence to treatment trial.

Authors:  Karen Glanz; Allen D Beck; Lucja Bundy; Susan Primo; Michael J Lynn; Julia Cleveland; Jessica A Wold; Katharina V Echt
Journal:  Arch Ophthalmol       Date:  2012-10

Review 3.  The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature.

Authors:  Marcia Vervloet; Annemiek J Linn; Julia C M van Weert; Dinny H de Bakker; Marcel L Bouvy; Liset van Dijk
Journal:  J Am Med Inform Assoc       Date:  2012-04-25       Impact factor: 4.497

4.  The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP.

Authors:  Suzan Guven Yilmaz; Cumali Degirmenci; Yunus Emre Karakoyun; Emil Yusifov; Halil Ates
Journal:  Int Ophthalmol       Date:  2017-06-14       Impact factor: 2.031

5.  Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: an exploratory randomised controlled trial.

Authors:  T A Gray; C Fenerty; R Harper; A F Spencer; M Campbell; D B Henson; H Waterman
Journal:  Eye (Lond)       Date:  2011-11-18       Impact factor: 3.775

Review 6.  The medical and surgical treatment of glaucoma.

Authors:  Thomas S Dietlein; Manuel M Hermann; Jens F Jordan
Journal:  Dtsch Arztebl Int       Date:  2009-09-11       Impact factor: 5.594

7.  Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review.

Authors:  Gregory Reardon; Sameer Kotak; Gail F Schwartz
Journal:  Patient Prefer Adherence       Date:  2011-09-23       Impact factor: 2.711

8.  Patterns of adherence behaviour for patients with glaucoma.

Authors:  H Cate; D Bhattacharya; A Clark; R Holland; D C Broadway
Journal:  Eye (Lond)       Date:  2013-01-18       Impact factor: 3.775

9.  Adherence to ocular hypotensive therapy: patient health education needs and views on group education.

Authors:  Heather Waterman; Lisa Brunton; Cecilia Fenerty; Jane Mottershead; Cliff Richardson; Fiona Spencer
Journal:  Patient Prefer Adherence       Date:  2013-01-18       Impact factor: 2.711

10.  Protocol for a randomised controlled trial to estimate the effects and costs of a patient centred educational intervention in glaucoma management.

Authors:  Heidi Cate; Debi Bhattacharya; Allan Clark; Richard Fordham; Caitlin Notley; David C Broadway
Journal:  BMC Ophthalmol       Date:  2012-11-22       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.